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Many lead compounds in the search for new drugs
derive from peptides and polyketides whose similar
biosynthetic enzymes have been difficult to engineer
for production of new derivatives. Problems with
generating multiple analogs in a single experiment
along with lack of high-throughput methods for
structure-based screening have slowed progress in
this area. Here, we use directed evolution and amulti-
plexed assay to screen a library of >14,000 members
to generate three derivatives of the antibacterial
compound, andrimid. Another limiting factor in reen-
gineering thesemega-enzymes of secondary metab-
olism has been that commonly used hosts such as
Escherichia coli often give lower product titers, so
our reengineering was performed in the native
producer, Pantoea agglomerans. This integrated
in vivo approach can be extended to larger enzymes
to create analogs of natural products for bioactivity
testing.
INTRODUCTION
Nonribosomal peptides are a proven source of antibacterial
(Recktenwald et al., 2002), antifungal (Denning, 1997), and anti-
cancer drugs (Du et al., 2000). These peptides often contain
nonproteogenic amino acids as well as fatty acid, polyketide,
carbohydrate, and isoprenoid appendages. The enzymes that
build these modified peptides, nonribosomal peptide synthe-
tases (NRPSs), are often large enzymes with multiple active sites
and are characterized by keeping intermediates covalently teth-
ered by a series of phosphopantetheine (PPant) linked thioester
bonds at the thiolation (T) domains during biosynthesis. The
gatekeepers of these molecular ‘‘assembly lines’’ are the adeny-Chemistry & Biology 18,lation (A) domains which select an amino acid building block
from the pool available within producing cells. The modular
structure of NRPSs make them attractive targets for protein
engineering, but realization of this goal over the last few decades
has been farmore difficult thanmany had hoped. Herewe screen
a library of 14,330 clones for derivatives of the antibiotic
andrimid (1). Focusing on the site of valine incorporation, three
new chemical derivatives have been created with similar or
improved biological activity.
Even though amino acid substrates for adenylation domains
may be predicted with some confidence via the ‘‘NRPS Code’’
(Challis et al., 2000; Rausch et al., 2005; Stachelhaus et al.,
1999), engineering of these domains to accept noncognate
substrates has been elusive. Often referred to as combinatorial
biosynthesis (Khosla et al., 1999; Khosla and Zawada, 1996;
Tsoi and Khosla, 1995; Walsh, 2002; Walsh et al., 2003),
a main approach has employed chimeric synthetases where an
adenylation domain of one NRPS is replaced by an adenylation
domain from another NRPS which activates a different
substrate. This so-called ‘‘domain swapping’’ strategy has
proved successful in terms of generating the desired product,
but has been plagued by decreased product yields and outright
dysfunction presumably due to interruption of protein-protein
interactions caused by this cut and paste approach (Baltz
et al., 2006; Doekel and Marahiel, 2000; Mootz et al., 2000,
2002; Nguyen et al., 2006; Schneider et al., 1998; Stachelhaus
and Marahiel, 1995a, 1995b). The activity of chimeric synthe-
tases could be restored in the first reported use of directed
evolution for reengineering NRPS systems (Fischbach et al.,
2007). Domain swapping, however, is still not ideal for true
combinatorial biosynthesis in that at most one variant of an
NRP can be generated per swap. Here, we present the second
example of using directed evolution to alter thiotemplated
biosynthetic systems. Instead of rescuing activity of a chimeric
synthetase using error-prone PCR, we directly targeted active
site residues for evolution using saturation mutagenesis (Chock-
alingam et al., 2005). This orthogonal approach to NRPS reen-
gineering focuses on modifying the sites of substrate specificity,601–607, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 601
N
H
N
H
O O
O
NH
O
O
N
H
O O
N
H2+
O
O
NH
O
O
N
H+
O
N
H
N
H
O O
O
NH
O
O
N
H
N
H
O O
O
NH
O
O
N
H
N
H
O O
O
NH
O
O
N
H
N
H
O O
O
NH
O
O
Figure 1. Workflow for Directed Evolution of AdmK
After deletion of admK from the P. agglomerans chromosome and trans-
formation with a library of admK mutants, the library is screened by high-
throughput LC-MS/MS. New compounds are identified and assayed for
bioactivity. See also Figure S1.
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Evolution of AdmK Generates Andrimid Derivativesrather than modifying the protein-protein interactions of the A-
and T-domains as in a previous study (Fischbach et al., 2007).
By targeting mutations to the substrate binding site and gener-
ating hundreds of enzyme variants in parallel, we created a large
library of mutants, each with the potential to generate a natural
product derivative. Further, we used mass spectrometry as
a structure-based readout for the library. Ultimately, four
mutants that produce robust levels of new derivatives were
found. The workflow for this study is illustrated in Figure 1.
The system under study here is the andrimid biosynthetic
pathway (Figure 2). Andrimid (1) is a hybrid NRP/PK molecule
produced by P. agglomerans (Fredenhagen et al., 1987; Jin
et al., 2006; Singh et al., 1997). Andrimid is a broad spectrum
antibiotic and acts by inhibiting fatty acid biosynthesis at the
acetyl CoA carboxylase step, preventing formation of malonyl
CoA, the precursor for fatty acids and some polyketides (Frei-
berg et al., 2004). Previous structure-activity relationship (SAR)
studies identified a portion of andrimid, the valine subunit, that
could be exchanged to create more potent and specific
compounds (Freiberg et al., 2006). Domain swapping experi-KS CLF DH T TG A T TG A
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602 Chemistry & Biology 18, 601–607, May 27, 2011 ª2011 Elsevierments on the corresponding NRPS gene, admK, showed that
the valine subunit could be substituted for isoleucine or amino-
butyrate and that there was no apparent editing by downstream
condensing enzymes (Belshaw et al., 1999), allowing generation
of andrimid derivatives in vivo (Fischbach et al., 2007).RESULTS
Library Design and Construction
We sought to express a library of mutant enzymes and monitor
the effectiveness of the mutations by screening for end products
produced by the pathway in vivo. To accomplish this, removal of
the wild-type (WT) enzyme activity was necessary. We employed
an allele replacement strategy based on homologous recombi-
nation that has proved successful in a number of organisms,
namely the streptomycin resistance counterselection (Russell
and Dahlquist, 1989). Using this strategy, we made a scarless
deletion of the WT admK gene in P. agglomerans. The resulting
strain served as a background strain for expression of an
admKmutant library (see Figure S1A available online). This result
was validated by PCR (Figure S1B). Also, we found that the
E. coli expression plasmid pQE60 was capable of supplying
admK and restoring andrimid production levels comparable to
WT in P. agglomerans (Figure S1C).
In order to select residues in admK for mutagenesis, we turned
to sequence alignments of AdmKwith A-domains known to acti-
vate substrates different than the valine found in andrimid (Fig-
ure S3). We chose A-domains that activate nonpolar amino acids
because SAR studies (Freiberg et al., 2006) showed that this type
of residue could substitute for valine and increase the potency
and selectivity of the andrimid scaffold. From the sequence
alignment with the ten residues used for substrate prediction
of NRPS A-domains (Stachelhaus et al., 1999), we chose the
three most highly variant of the ten for saturation mutagenesis
(Miyazaki and Arnold, 1999) (Figure 3). Our three-site saturation
mutagenesis library was designed to create 1404 distinct
mutants, and was limited by selection of codons for synthetase
residues likely to select nonpolar substrates (Figure 3) for incor-
poration into the andrimid backbone. The mutant library was
constructed by utilizing sequential megaprimer and overlap
extension PCRs (Horton, 1997; Sarkar and Sommer, 1990). InA
T
KS T TE
Figure 2. Andrimid Biosynthetic Pathway
Andrimid is biosynthesized by a highly discon-
nected and hybrid NRPS/PKS pathway.
Adenylation domain substrate specificity is indi-
cated by single letter amino acid abbreviation
subscript. AdmK incorporates the valyl subunit
(highlighted) of andrimid and has been targeted
for mutagenesis. KS- ketosynthase, CLF- chain
length factor, DH-dehydrogenase, KR- ketor-
eductase, T-thiolation, TG-transglutaminase,
A-adenylation, Mut- aminomutase, C- condensa-
tion, TE-thioesterase.
Ltd All rights reserved
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Figure 4. Structures of Andrimid and Derivatives Produced in This
Study
1 andrimid, 2 octatrienyl-b-phenylalnine, 3 octatrienyl-b-phenylalanyl-b-phenyl-
alanine, 4 isoleucine-andrimid, 5 leucine-andrimid, 6 alanine-andrimid, 7 phenyl-
alanine-andrimid. See also Figure S4.
 235 236 239 278 299 301 322 330 331 517
GrsA(Phe) D A W T I A A I C K
TycB(Phe) D A W T I A G V C K
McyA(Ala) D L F N N A L T Y K
JamO(Ala) D L F N N A L T Y K
BacA(Ile) D G F F L G V V Y K
FenB(Ile) D A F F Y G I T F K
SrfAB(Leu)D A W F L G N V V K
GrsB(Leu) D G A Y T G E V V K
LicB(Val) D A F W I G I T F K
AdmK(Val) D A F W I G G V F K
   (GrsA Numbering) 
   (AdmK Numbering) 
Figure 3. Extracted Nonribosomal Code Residues
Nonribosomal code residues extracted from adenylation domains from GrsA,
AdmK and other systems with consensus sequences for nonpolar amino acids
(shown in parentheses). Strictly conserved residues are highlighted in blue,
highly conserved residues are highlighted in green and highly variant residues
targeted for limited saturation mutagenesis are highlighted in red. See also
Figure S3.
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Evolution of AdmK Generates Andrimid Derivativesorder to make a library that maximized the amino acid substitu-
tions we desired, while minimizing unwanted substitutions
truncations, PCR primers with limited degeneracy were used.
Position 240 of AdmK was mutagenized using a WHK codon in
place of the native TGG codon substituting the native Trp with
Met, Thr, Ser, Tyr, Leu, Phe, Ile, Asn, and Lys and only one
possible stop codon. For position 265 of AdmK, a WHW codon
replaced the native ATC codon thereby substituting Leu, Phe,
Thr, Tyr, Asn, Lys, and one possible stop codon for Ile. Position
291 of AdmK was mutagenized by using an RHK codon in place
of theWTGGT codon in order to substitute Val, Ile, Asn, Ala, Glu,
Met, Thr, Lys, and Asp for Gly with no possibility for a truncation
at this position. Together, these three degenerate codons allow
for 1404 codon combinations. To ensure 95% coverage of
1404 mutants, we screened 14,330 clones. Statistical analysis
using the program GLUE (Patrick et al., 2003) estimated that
the library was 99.99% complete with a 94.9% probability that
the library contained all possible variants.
Assay Development and Library Screening
To screen our library of andrimid producing clones, we em-
ployed a structure-based assay. We reasoned that using an
antibiotic bioassay we would not be able to distinguish
between andrimid and derivatives of andrimid. Also, we would
be incapable of identifying which precise andrimid derivative
had been produced because most derivatives would likely be
active antibiotics (Freiberg et al., 2006). During evaluation,
mass spectrometric detection of andrimid showed 23,000-
fold greater sensitivity than a bioassay, and we noticed a frag-
mentation pattern that cleanly dissected the molecule into
regions to be conserved or variant (Figure 1, lower right panel).
This calculation of relative sensitivity for MS versus classic halo
assays is based on the limit of detection (LOD) during MS of an-
drimid, which is 20 fmol. Given that 96 samples are mixed perChemistry & Biology 18,LC-MS injection, this translates to a LOD of 1.9 pmol for the
pooled assay. The MIC data for andrimid against E. coli show
that 0.47 nmol can be detected in a 10 ml spot in the agar over-
lay assay. If this assay were diluted 96-fold as in the LC-MS
assay this translates to a 45.1 nmol LOD. These attributes of
the MS-based screen allowed us to identify which andrimid
derivative was produced and conduct the screening of 96
clones in a single LC-MS run. Single clones arrayed into
96-well plates, were inoculated into 23YT microbial medium
supplemented only with antibiotic and grown for 24 hr prior
to pooled sampling of each 96-well plate. Each pooled sample
representing 96 individual clones constituted one LC-MS/MS
injection. In this way, over 14,330 clones from 150 individual
96-well plates of the three site library were screened and four
clones producing andrimid derivatives were isolated. Twenty-
four percent of assay plates (i.e., 96 samples combined into
one) still showed production of andrimid while 41% of plates
showed no production beyond the octatrienyl-b-phenylalanine
precursor to andrimid (a truncated product, 2). Curiously,
almost all of the plates assayed showed production of a species
at m/z 433.21 that was determined to be octatrienyl-b-phenyl-
alanyl-b-phenylalanine (3), a result of apparent ‘‘stuttering’’ by
the transglutaminase AdmF, the enzyme responsible for in-
corporating b-phenylalanine into the growing ketide-peptide
chain.
Characterization of Mutants and Derivative Compounds
The four mutant clones were identified subsequently (by pooled
-row and -column searching of assay plates), sequenced and
designated A2 (W240L, G291V), A7 (W240S, I265T, G291E), A9
(W240T, I265T, G291E), and B12 (R235K, W240L, I265L,
G291E). Together, these clones produced three new andrimid
derivatives and another that has been described previously (Fig-
ure 4; Figure S4A, i-iv). Clones A2 and B12 were found to601–607, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 603
Figure 5. Andrimid and Derivatives Bioassay
Agar-overlay bioassay of andrimid and analogs generated against E. coli imp
ASR. Aliquots of each compound (numbered) and a solvent negative control (–)
were spotted onto paper disks atop a layer of soft agar seeded with E. coli.
Table 1. Mutations in admK and Corresponding Products
Compared with WT Production Levels
Clone Mutations
Compound
Produced Medium
Production
per Liter (mg)
WT N/A 1 2xYT 378.16
A2 W240L, G291V 4 2xYT + Ile 4.94
5 2xYT + Leu 0.99
B12 R235K, W240L,
I265L, G291E
4 2xYT + Ile 466.39
5 2xYT + Leu 93.83
A7 W240S, I265T,
G291E
6 2xYT + Ala 0.19
7 2xYT + Phe 0.36
A9 W240T, I265T,
G291E
6 2xYT + Ala 0.20
7 2xYT + Phe 0.49
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Evolution of AdmK Generates Andrimid Derivativesproduce an andrimid related peak atm/z 494.26, corresponding
to either isoleucine- or leucine-substituted andrimid (4, 5)
(Figure S4A, i, ii). Clones A7 and A9 produced a mixture of
alanine- and phenylalanine-substituted andrimid (6, 7) (Fig-
ure S4A, iii, iv). In order to resolve the L-Ile versus L-Leu ambi-
guity for clones A2 and B12, an isotope feeding study was
conducted. Growing clones A2 and B12 in media supplemented
with a 50:50 mixture of 13C2-Leu and
13C6-Ile demonstrated that
both clones A2 and B12 have preference for Ile over Leu, but at
different levels of discrimination (Figure S4B). Clone A2 showed
a 4:1 preference for Ile to Leu, whereas clone B12 showed a 20:1
preference for Ile to Leu. Control experiments where only one
isotope labeled amino acid was supplemented clearly showed
that when one amino acid is supplied in 50 mM excess, incorpo-
ration of that amino acid is efficient (Figure S4C). For that reason,
we employed a mutasynthesis strategy where the desired amino
acid to be incorporated was supplied in excess for scale up of
fermentations in order to determine yield and bioactivity. We
found that applying this mutasynthesis strategy also improved
the yield for clones A7 and A9. Compounds 1, 4, 5, and 7 were
all found to be bioactive in disk diffusion assays (Figure 5).
When using the mutasynthesis, we were able to significantly
improve the yields, in some cases approaching WT levels (Table
1; Figure S5). MICs were determined for several representative
bacterial strains (Table 2).Table 2. MIC Data for Andrimid and Derivatives against
Representative Gram-Negative and Gram-Positive Bacterial
Strains
MIC (nmol)
1 4 5
E. coli imp ASR 0.47 2.72 0.73
K. pneumoniae ATCC 13883 9.05 2.93 NTa
S. aureus ATCC 25923 7.71 0.39 0.28
E. faecalis ATCC 19433 36.35 42.76 NTa
aNot tested.DISCUSSION
This work takes on the challenges associated with engineering
enzymes of secondary metabolism with a technological
approach that applies generally to metabolites detectable by
tandem mass spectrometry. When combined with high level
expression in the native host, P. agglomerans, the reduced
metabolic production from active site mutation of admK (largely
from poor solubility of variants), did not prevent four successes
from being found in a library pool where 80% were unaffected,
20% were dead, and 0.03% had altered production.
Creating a mutant library of admK rather than performing
several domain-swapping experiments allowed us to generate604 Chemistry & Biology 18, 601–607, May 27, 2011 ª2011 Elsevierfour andrimid derivatives in the same overall experiment while
examining many solutions for each derivative simultaneously.
The key aspect of our work that allowed for this combinatorial
biosynthesis experiment is the structure-based assay that
provided a direct readout of not just the AdmK variants’ activity,
but also the combined output of downstream enzymes in the
assembly line. Unlike many indirect assays of enzyme activity
(bioactivity or coupled assays), direct structural readout of
mutant activity in the integrated pathway tightly connects the
overall impact of the mutagenesis with a main goal of the exer-
cise: production of new derivatives.
We found four mutants that exhibited altered substrate spec-
ificity, A2, A7, A9, and B12. All showed a broadening of substrate
specificity relative to the WT, with increased preference to
substrates other than the cognate substrate, valine. To our
surprise, the overall best performingmutantwas actually a seren-
dipitous quadruple mutant. The fourth mutation in B12, R235K is
likely an artifact of PCR; however, it is unknown if this straymuta-
tion is required for robust production of the Ile/Leu analogs.
Structures for NRPS A-domains available exhibit low sequence
identity to AdmK, 25% for 1AMU and 24% for 2VSQ. However,
based on alignment of AdmK to the structures above, R235
corresponds to N697 of 2VSQ and E272 of 1AMU. These posi-
tions in the respective crystal structures are remote from the
active site and on the surface of the protein. We can only spec-
ulate that R235K may change a protein-protein interaction
surface or induce a structural change to the active site through
an outer sphere effect. The relatively higher activity and solubility
of the B12 mutant over the others suggests that mutationsLtd All rights reserved
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Evolution of AdmK Generates Andrimid Derivativesoutside the selectivity conferring code should be considered for
future A-domain mutant libraries. A second round of mutagen-
esis and screening was performed on the four isolated clones
using an error-prone PCR approach in order to increase the
activity of the first round mutants, but no improvement was
observed. MIC values for the derivative compounds 4 and 5
showed increased bioactivity toward Staphylococcus aureus
relative to 1, and unchanged or decreased bioactivity toward
E. coli consistent with previous SAR studies (Freiberg et al.,
2006) (Table 2). Prediction of A-domain substrates is fairly robust
(Rausch et al., 2005). Despite this, prescription of what active site
mutations to make for a particular metabolite structure is far less
developed. This study provides a large-scale survey of what
amino acid substitutions could be tolerated in the A-domain
active site. While many of the triple mutants that still yielded an-
drimid were not sequenced here, one can envisage a large-scale
study specifically aimed at determining empirically what sites are
stable to mutation. This would effectively map functional
outcomes for many positions and sharply increase our predictive
ability for creation of new NRPS derivatives.
One reason the andrimid system was chosen is because its
biosynthetic enzymes are mostly < < 100 kDa (i.e., relatively
small for NRPS or PKS proteins). There is no reason why our
methods cannot be extended to larger multimodule NRPSs,
provided the host is genetically tractable, or the pathway is
amenable to heterologous expression with robust yields. We
envision that the general approach used here could be extended
to other domains within NRPS systems to probe substrate spec-
ificity of condensation domains. We estimate that a 100-fold
improvement in screening speed could be achieved, leading to
an ability to screen 4 or even 5 site mutant libraries with similar
coverage within the same approximate scope of time and
resources used in this work.
Peptide natural products from NRPS systems draw high
interest because of their medical uses, but harnessing their
rather predictable correlation between enzyme primary structure
and metabolite structure has proved elusive over the past two
decades (Khosla et al., 1999). Reengineering strategies to
achieve combinatorial biosynthesis (Walsh, 2002) compete
conceptually with organic synthesis as a strategy for enhancing
the diversity of natural molecular scaffolds. Challenges to attain-
ing the goal of true combinatorial biosynthesis include not only
the general challenges of enzyme engineering, but also the
methods used to evaluate the modified enzymes and pathways.
The field of NRPS reengineering is making strides through better
understanding of protein-protein recognition motifs (Li and
Vederas, 2009) and the use of directed evolution (Fischbach
et al., 2007) to generate libraries of A-domains capable of
activating a variety of substrates. Alternative approaches to
making mutant libraries such as family shuffling (Crameri et al.,
1998) could be employed in the future to generate even larger
libraries of large active site fragments, perhaps leading to more
stable and active mutant enzymes.
SIGNIFICANCE
Combinatorial biosynthesis is an attractive alternative to
chemical synthesis for creating analogs of complex natural
products. A major hurdle to realizing the potential of combi-Chemistry & Biology 18,natorial biosynthesis includes the lack of selections or
screens to process mutant libraries of enzymes in the
context of their entire biosynthetic pathway. This work
demonstrates a general method for rapidly generating and
screening mutant libraries of nonribosomal peptide synthe-
tases. The unbiased nature of structure-based screening
allows for evaluation of the output from entire mutant path-
ways on a basis largely disconnected from total yield or
specific bioactivity. Using the high-throughput multiplexed
LC-MS/MS screeningmethod outlined here, four derivatives
of the antibiotic andrimid were generated, three of them not
previously reported. The relative bioactivities of the deriva-
tives were measured and it was found that two of the deriv-
atives exhibited a shift in antibacterial specificity with
concomitant decreases in their MIC values, consistent
with previous synthetic chemistry driven SAR studies. Muta-
genesis combined with LC-MS/MS for a structure-based
readout is a general approach that can be readily extended
to other nonribosomal peptide synthetase and polyketide
synthase pathways as well as to other biosynthetic pathway
paradigms.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
Restriction enzymes were from Invitrogen (Carlsbad, CA), T4 DNA ligase was
fromNewEnglandBiolabs (Ipswich,MA), Phusion polymerase fromFinnzymes
(Woburn, MA) was used for PCR. Growth medium was from BD Biosciences
(San Jose, CA). Oligonucleotides were purchased from Integrated DNA Tech-
nologies (Coralville, IA) and are listed in Supplemental Experimental Proce-
dures. HPLC solvents were from Fisher (Pittsburgh, PA). Formic Acid was
from Acros Organics (Geel, Belgium). PCR cleanup, plasmid miniprep and
gel extraction kits were from QIAGEN (Valencia, CA). Stable-isotope labeled
amino acids were from Cambridge Isotopes (Andover, MA). All other reagents,
chemical and consumables were from Sigma unless otherwise specified.
Strains and Plasmids
E. coliDH5a l pir was used for all cloning steps for plasmids containing oriR6K.
E. coli DH5a and BL21(DE3) were obtained from the UIUC Cell Media Facility.
E. coli imp ASR, Klebsiella pneumoniae ATCC 13883, Staphylococcus
aureus ATCC 25923, and Enterococcus faecalis ATCC 19433 were used as
the indicator strains for agar overlay assays. The andrimid producer,
P. agglomerans Eh 335 and E. coli imp ASR were a gift from Christopher
T. Walsh. K. pneumoniae ATCC 13883, S. aureus ATCC 25923, and
E. faecalis ATCC 19433 were obtained from ATCC (Manassas, VA). All strains
were cultured in LB or 2xYT at 37C (E. coli, K. pneumoniae, S. aureus, and
E. faecalis) or 28C (P. agglomerans). Plasmid pQE60 (QIAGEN) was used
for expression of admK in P. agglomerans. Plasmids pACYC-Duet, pET-Duet,
pET28a, and pUC-19 were obtained from Novagen (Darmstadt, Germany).
The suicide plasmid pMQ118 was obtained from Presque Isle Cultures
(Erie, PA). All strains and plasmids are listed with relevant characteristics in
Supplemental Experimental Procedures.
Antibiotic Bioassays
LB agar plates (100mmdiameter) were overlaid with 4ml molten LB agar inoc-
ulated with 75 ml of an overnight culture of the indicator strain. The inoculated
top agar was allowed to solidify before sterile paper disks were laid onto the
assay plates. Onto each disk 10–20 ml of sterile filtered culture supernatant
or control was spotted before incubation at 37C overnight or until zones of
inhibition were visible.
DNA Sequencing
DNA sequencing was carried out at the University of Illinois core sequencing
facility on an ABI 3730XL capillary sequencer on reactions using BigDye601–607, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 605
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Evolution of AdmK Generates Andrimid DerivativesVersion 3.0 terminator/enzymemix and standard protocols. Sequence outputs
were assembled and analyzed using Sequencher 4.6 software (Gene Codes,
Ann Arbor, MI).Mass Spectrometry
A 7 Tesla LTQ-FT equipped with a Surveyor autosampler and a MS pump was
used for all mass spectrometric analysis (Thermo-Fisher Scientific). Andrimid
and its derivatives were analyzed using a Jupiter 4.6 3 150 mm C18 HPLC
column (Phenomenex) and a gradient of 0%–75% ACN over 35 min. LC
solvents (water and acetonitrile) contained 0.1% formic acid. Initial screening
was performed at low (ion-trap) resolution with a selected ion monitoring (SIM)
window fromm/z 435–535 as the full scan and data-dependent fragmentation
of the top 10 peaks from the full scan. Confirmation of derivative production
was carried out using the same scans but in high (FT, 100,000) resolution.
Mass spectrometric data were analyzed using Qual Browser software
(Thermo-Fisher Scientific).Molecular Genetics
Please refer to Supplemental Experimental Procedures for detailed methods
for genetic manipulation of P. agglomerans.Alignment of AdmK to Other Adenylation Domains and Extraction
of Binding Pocket Residues
Several adenylation domains with specificity for the desired activity in the
AdmK (GenBank accession number AAO39105.1) were aligned: GrsA
(GenBank accession number CAA33603.1, phenylalanine specific), TycB M3
(GenBank accession number AAC45929.1, phenylalanine specific), McyA
M2 (GenBank accession number CAO90227.1, alanine specific), JamO_
(GenBank accession number AAS98786.1, alanine specific), BacA M1
(GenBank accession number AAC06346.1, isoleucine specific), FenB (Gen-
Bank accession number AAB00093.1, isoleucine specific), SrfAB M3 (Gen-
Bank accession number BAA08983.1, leucine specific), GrsB M4 (GenBank
accession number CAA43838.1, leucine specific) and LicB M1 (GenBank
accession number AAD04758.1, valine specific). Adenylation domains were
aligned using the program CLUSTALX (Thompson et al., 1997) (Figure S3).
Positions aligning to D235, A236, W239, T278, I299, A301, A322, I330,
C331, and K517 of GrsA were extracted as the putative binding pocket resi-
dues (Stachelhaus et al., 1999). The binding pocket residues were inspected
for their variation across the aligned sequences and three positions corre-
sponding to T278, I299, and A322 in GrsA were chosen for mutagenesis.Construction and Screening of admK Mutant Library
Please refer to Supplemental Experimental Procedures for detailed methods
for construction and screening of the admK mutant library.Isolation and Quantification of Andrimid and Analogues
Andrimid was produced from liquid culture of P. agglomerans in 2xYT supple-
mented with antibiotics and amino acids as required for 28C for 24 hr. Cells
were removed by centrifugation followed by filtration through a 0.45 mm
membrane (Millipore, Billerica,MA). Filtered culture supernatant was extracted
three times with one-half volume ethyl acetate. Ethyl acetate fractions were
combined and dried under vacuum. The crude extract was dissolved in
50:50 water: methanol and extracted with 9 volumes of hexane. The water:me-
thanol fraction was then extracted with one half volume methylene chloride.
The methylene chloride fraction was dried under vacuum and then dissolved
in 10 ml 20% acetonitrile and applied to a 12 cc C18 SPE column (Whatman,
Piscataway, NJ) equilibrated with 20% acetonitrile. The column was washed
with 2 volumes 40% acetonitrile and eluted with one volume 80% acetonitrile.
The eluate was dried and dissolved in 20%acetonitrile then loaded onto a 103
150 mm Eclipse C18 column (Agilent, Santa Clara, CA). Andrimid and analogs
were eluted from the column using a linear gradient 0%–70% acetonitrile over
30 min. Andrimid and analogs eluted as pure peaks from 25 to 32 min. Peak
purity and yield were determined by a LC-MS assay using the same column,
gradient and mass spectrometer used in screening the mutant library cali-
brated with standards at known concentrations.606 Chemistry & Biology 18, 601–607, May 27, 2011 ª2011 ElsevierStable Isotope Feeding Study
Mutants A2 and B12 were grown in M9 medium supplemented with 0.1%
yeast extract, 0.1% casamino acids and 50 mM each of 13C2 leucine and/or
13C6 isoleucine (Cambridge Isotopes) for 24 hr at 30
C. The culture superna-
tants were syringe filtered and analyzed using the LC-MS/MSmethod outlined
above.MIC Determination
LB agar plates (140 mm diameter) were overlaid with 12 ml molten LB agar
inoculated with 225 ml of OD600 = 0.8 indicator strain. The inoculated top
agar was allowed to solidify before sterile paper disks were laid onto the assay
plates. Tenmicroliters of antibiotic was spotted onto the disks and plates were
incubated 8 hr at 37C. Zones of inhibition were defined as the radius and
measured using calipers. Zones of inhibition were plotted against Log10 of
the concentration of spotted antibiotic. MICs were defined as the minimum
concentration required to yield a 1 mm zone of inhibition and calculated by
nonlinear regression using the software package GraphPad Prism (La
Jolla, CA).SUPPLEMENTAL INFORMATION
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